Milestone Pharmaceuticals to Present at the Piper Sandler 36th Annual Healthcare Conference

GlobeNewswire

2024-11-25

Milestone Pharmaceuticals Logo.png

MONTREAL and CHARLOTTE, N.C., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that President and CEO, Joe Oliveto, and Chief Commercial Officer, Lorenz Muller, will participate in a fireside chat at the Piper Sandler 36^th Annual Healthcare Conference on December 4, 2024, at 10:30 a.m. Eastern Time.

A live webcast of the fireside chat will be available to conference participants. If you are interested in viewing the fireside chat or meeting with the Milestone team during the conference, email corporateaccess@psc.com.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat episodic attacks associated with PSVT and AFib-RVR.

Contact:
Kim Fox,
Vice President, Communications,
kfox@milestonepharma.com

Investor Relations
Chris Calabrese, ccalabrese@lifesciadvisors.com

Kevin Gardner, kgardner@lifesciadvisors.com

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2486108933"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2486108933\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2486108933?lang=zh_TW&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OS87CBXtctSsmEhMynu6Cg--~B/aD05MTt3PTQ3NzthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/f37cd6a293939eb8db299f5dd6d91bc9","is_english":true,"pubTime":"2024-11-25 21:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2486108933","market":"us","top_or_hot":-1,"title":"Milestone Pharmaceuticals to Present at the Piper Sandler 36th Annual Healthcare Conference","media":"GlobeNewswire","content":"<html><body><img hspace=\"5\" src=\"https://s1.yimg.com/uu/api/res/1.2/_NKHHpiaQKiegKgTSW_Eqg--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/a3e01b195c1ef10ed327d66d987e808c\" title=\"Milestone Pharmaceuticals Logo.png\" vspace=\"5\"/>\n<p>MONTREAL and CHARLOTTE, N.C., Nov. 25, 2024 (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/MIST\">Milestone Pharmaceuticals Inc.</a> (Nasdaq: MIST) today announced that President and CEO, Joe Oliveto, and Chief Commercial Officer, Lorenz Muller, will participate in a fireside chat at the Piper Sandler 36<sup>th</sup> Annual Healthcare Conference on December 4, 2024, at 10:30 a.m. Eastern Time.</p>\n<p>A live webcast of the fireside chat will be available to conference participants. If you are interested in viewing the fireside chat or meeting with the Milestone team during the conference, email corporateaccess@psc.com.</p>\n<p><strong>About Milestone Pharmaceuticals</strong></p>\n<p>Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat episodic attacks associated with PSVT and AFib-RVR.</p>\n<p><strong>Contact:</strong><br/>Kim Fox, <br/>Vice President, Communications, <br/>kfox@milestonepharma.com<br/><br/><br/></p>\n<p>Investor Relations<br/>Chris Calabrese, <u>ccalabrese@lifesciadvisors.com</u><br/></p>\n<p>Kevin Gardner, <u>kgardner@lifesciadvisors.com</u></p>\n<br/></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Milestone Pharmaceuticals to Present at the Piper Sandler 36th Annual Healthcare Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMilestone Pharmaceuticals to Present at the Piper Sandler 36th Annual Healthcare Conference\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">GlobeNewswire</strong><span class=\"h-time small\">2024-11-25 21:00</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><img hspace=\"5\" src=\"https://s1.yimg.com/uu/api/res/1.2/_NKHHpiaQKiegKgTSW_Eqg--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/a3e01b195c1ef10ed327d66d987e808c\" title=\"Milestone Pharmaceuticals Logo.png\" vspace=\"5\"/>\n<p>MONTREAL and CHARLOTTE, N.C., Nov. 25, 2024 (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/MIST\">Milestone Pharmaceuticals Inc.</a> (Nasdaq: MIST) today announced that President and CEO, Joe Oliveto, and Chief Commercial Officer, Lorenz Muller, will participate in a fireside chat at the Piper Sandler 36<sup>th</sup> Annual Healthcare Conference on December 4, 2024, at 10:30 a.m. Eastern Time.</p>\n<p>A live webcast of the fireside chat will be available to conference participants. If you are interested in viewing the fireside chat or meeting with the Milestone team during the conference, email corporateaccess@psc.com.</p>\n<p><strong>About Milestone Pharmaceuticals</strong></p>\n<p>Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat episodic attacks associated with PSVT and AFib-RVR.</p>\n<p><strong>Contact:</strong><br/>Kim Fox, <br/>Vice President, Communications, <br/>kfox@milestonepharma.com<br/><br/><br/></p>\n<p>Investor Relations<br/>Chris Calabrese, <u>ccalabrese@lifesciadvisors.com</u><br/></p>\n<p>Kevin Gardner, <u>kgardner@lifesciadvisors.com</u></p>\n<br/></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.yahoo.com/news/milestone-pharmaceuticals-present-piper-sandler-130000760.html\">GlobeNewswire</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HCSG","symbol_name":"醫療保健服務","start_time":0,"source_url":"https://finance.yahoo.com/news/milestone-pharmaceuticals-present-piper-sandler-130000760.html","article_id":"2486108933","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OS87CBXtctSsmEhMynu6Cg--~B/aD05MTt3PTQ3NzthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/f37cd6a293939eb8db299f5dd6d91bc9"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486108933","pubTimestamp":1732539600,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"MONTREAL and CHARLOTTE, N.C., Nov. 25, 2024  -- Milestone Pharmaceuticals Inc.  today announced thatPresident and CEO, Joe Oliveto, and Chief Commercial Officer, Lorenz Muller, will participate in a fireside chat at the Piper Sandler 36thAnnual Healthcare Conference on December 4, 2024, at10:30 a.m. Eastern Time.A live webcast of the fireside chat will be available to conference participants. If you are interested in viewing the fireside chat or meeting with the Milestone team during the conference, email corporateaccess@psc.com.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"HCSG":"医疗保健服务","MIST":"Milestone Pharmaceuticals Inc.","BK4007":"制药","BK4137":"综合支持服务"},"translate_title":"Milestone Pharmaceuticals将出席Piper Sandler第36届年度医疗保健会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HCSG":1,"MIST":0.9},"content_text":"MONTREAL and CHARLOTTE, N.C., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that President and CEO, Joe Oliveto, and Chief Commercial Officer, Lorenz Muller, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024, at 10:30 a.m. Eastern Time.\nA live webcast of the fireside chat will be available to conference participants. If you are interested in viewing the fireside chat or meeting with the Milestone team during the conference, email corporateaccess@psc.com.\nAbout Milestone Pharmaceuticals\nMilestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat episodic attacks associated with PSVT and AFib-RVR.\nContact:Kim Fox, Vice President, Communications, kfox@milestonepharma.com\nInvestor RelationsChris Calabrese, ccalabrese@lifesciadvisors.com\nKevin Gardner, kgardner@lifesciadvisors.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}